Phosphotyrosine Signaling Proteins that Drive Oncogenesis Tend to be Highly Interconnected*

Mutation and overexpression of receptor tyrosine kinases or the proteins they regulate serve as oncogenic drivers in diverse cancers. To better understand receptor tyrosine kinase signaling and its link to oncogenesis, we used protein microarrays to systematically and quantitatively measure interactions between virtually every SH2 or PTB domain encoded in the human genome and all known sites of tyrosine phosphorylation on 40 receptor tyrosine kinases and on most of the SH2 and PTB domain-containing adaptor proteins. We found that adaptor proteins, like RTKs, have many high affinity bindings sites for other adaptor proteins. In addition, proteins that drive cancer, including both receptors and adaptor proteins, tend to be much more highly interconnected via networks of SH2 and PTB domain-mediated interactions than nononcogenic proteins. Our results suggest that network topological properties such as connectivity can be used to prioritize new drug targets in this well-studied family of signaling proteins.

[1]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[2]  G. MacBeath,et al.  Tyrosine-Phosphorylated Caveolin-1 Blocks Bacterial Uptake by Inducing Vav2-RhoA-Mediated Cytoskeletal Rearrangements , 2010, PLoS biology.

[3]  A. Barabasi,et al.  An empirical framework for binary interactome mapping , 2008, Nature Methods.

[4]  Takeshi Suzuki,et al.  RTCGD: retroviral tagged cancer gene database , 2004, Nucleic Acids Res..

[5]  T. Perren.  c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.

[6]  K. Rauen,et al.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.

[7]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[8]  A. Davidson,et al.  A Conserved Residue in the Yeast Bem1p SH3 Domain Maintains the High Level of Binding Specificity Required for Function* , 2011, The Journal of Biological Chemistry.

[9]  F. Bassermann,et al.  Association of Bcr-Abl with the Proto-oncogene Vav Is Implicated in Activation of the Rac-1 Pathway* , 2002, The Journal of Biological Chemistry.

[10]  David L Robertson,et al.  Effect of dataset selection on the topological interpretation of protein interaction networks , 2005, BMC Genomics.

[11]  J. Colicelli,et al.  ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity , 2010, Science Signaling.

[12]  Gavin MacBeath,et al.  Quantifying protein–protein interactions in high throughput using protein domain microarrays , 2010, Nature Protocols.

[13]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[14]  M. Quon,et al.  Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. , 2001, Endocrinology.

[15]  Shinichiro Wachi,et al.  Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues , 2005, Bioinform..

[16]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[17]  Philippe Dessen,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology, an Interactive Database , 2000, Nucleic Acids Res..

[18]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[19]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[20]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[21]  A. Gordus,et al.  System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. , 2008, Chemistry & biology.

[22]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[23]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[24]  A. Vazquez,et al.  Epstein–Barr virus and virus human protein interaction maps , 2007, Proceedings of the National Academy of Sciences.

[25]  Albert-László Barabási,et al.  Controllability of complex networks , 2011, Nature.

[26]  Brett W. Engelmann,et al.  SH2 Domains Recognize Contextual Peptide Sequence Information to Determine Selectivity* , 2010, Molecular & Cellular Proteomics.

[27]  U. Hellman,et al.  Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk. , 2003, Experimental cell research.

[28]  Martin Kircher,et al.  Deep proteome and transcriptome mapping of a human cancer cell line , 2011, Molecular systems biology.

[29]  E. Raymond,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy , 2012, Drugs.

[30]  S. Li,et al.  An Oriented Peptide Array Library (OPAL) Strategy to Study Protein-Protein Interactions* , 2004, Journal of Biological Chemistry.

[31]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[32]  R. Huddart,et al.  Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. , 2005, Cancer research.

[33]  G. MacBeath,et al.  Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling , 2011, Cell cycle.

[34]  J. Schlessinger,et al.  Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Pawson,et al.  The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. , 2006, Molecular cell.

[36]  Leslie M Loew,et al.  Molecular machines or pleiomorphic ensembles: signaling complexes revisited , 2009, Journal of biology.

[37]  Gavin MacBeath,et al.  A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. , 2008, Molecular bioSystems.

[38]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[39]  S. Roman,et al.  Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer , 2012, Clinical Medicine Insights. Oncology.

[40]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[41]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[42]  S. Lovell,et al.  Protein-protein interaction networks and biology—what's the connection? , 2008, Nature Biotechnology.

[43]  D. Morrison,et al.  Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.

[44]  Holger Conzelmann,et al.  Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. , 2011, Molecular cell.

[45]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[46]  H. Varmus,et al.  Binding of the Src SH2 domain to phosphopeptides is determined by residues in both the SH2 domain and the phosphopeptides , 1993, Molecular and cellular biology.

[47]  T Pawson,et al.  Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. , 1994, Oncogene.

[48]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[49]  N. Hacohen,et al.  A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.

[50]  A. Gordus,et al.  Tarp regulates early Chlamydia-induced host cell survival through interactions with the human adaptor protein SHC1 , 2010, The Journal of cell biology.

[51]  S. Fields,et al.  Protein analysis on a proteomic scale , 2003, Nature.

[52]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[54]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[55]  Peer Bork,et al.  Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy , 2011, Nucleic Acids Res..

[56]  P. Bork,et al.  Linear Motif Atlas for Phosphorylation-Dependent Signaling , 2008, Science Signaling.

[57]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[58]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[59]  Tony Pawson,et al.  Defining the Specificity Space of the Human Src Homology 2 Domain*S , 2008, Molecular & Cellular Proteomics.

[60]  J. Schlessinger,et al.  Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/SH2 domain binding. , 1993, Biochemistry.

[61]  M. Stratton,et al.  A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.

[62]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[63]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.